The primary objective of the Biostatistics Core in this P01 is to facilitate the understanding of the biology of melanomas and the development of novel strategies for melanoma treatment based on the most stringent and highest quality of statistical data analyses and inferences. The Biostatistics Core is well organized and equipped to achieve this goal. This Core will provide expertise on experimental design and critical analytical services to Investigators that are tailored to each project and provided in a timely and cost-effective manner. The biostatisticians in this Core will meet regularly with project investigators to develop analytic strategies, assess the statistical needs for each particular project on an ongoing basis, and to modify analysis plans as the research evolves. Since many elements of the statistical analysis plans will be specific to a particular study, each project will benefit from the centralized resource, including individuals who can provide expertise in study design, biostatistics methodology and specialized data analysis techniques and who have had significant experience in solving statistical issues in biological cancer research. This level of collaboration between Core biostatisticians and project Investigators will ensure that the quality and validity of each research project will be of the highest degree. In addition to the statistical services provided to each project, this Core is the essential centralized resource to integrate the data across all projects in this program and synthesize study findings. Using state of the art statistical techniques combined with high-throughput data garnered from each project, the Core will provide a clear and complete view of the associations between studied inhibitors and genotypes, and provide quantitative assessment regarding the development of novel strategies of melanoma treatment in this P01

Public Health Relevance

This Core is pivotal to ensure that the experimental design and data analyses within the Projects are done in a rigorous, integrated fashion, and to forge new directions in the translational components of the Program Project. This Core has a wealth of experience in cancer research that is used by the Program Project. The quantitative data analyses done by the Core allow us to better understand the associations between the studied inhibitors and genotypes of melanoma, as well as mechanisms of various combination therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-2 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Kaur, Amanpreet; Webster, Marie R; Marchbank, Katie et al. (2016) sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250-4
Budina-Kolomets, Anna; Webster, Marie R; Leu, Julia I-Ju et al. (2016) HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res 76:2720-30
Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2016) Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15:2012-24
Amaravadi, Ravi; Kimmelman, Alec C; White, Eileen (2016) Recent insights into the function of autophagy in cancer. Genes Dev 30:1913-30
Krepler, Clemens; Xiao, Min; Samanta, Minu et al. (2016) Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget :
Grasso, Michael; Estrada, Michelle A; Ventocilla, Christian et al. (2016) Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF(V600E) Conformation. ACS Chem Biol 11:2876-2888
Shannan, Batool; Chen, Quan; Watters, Andrea et al. (2016) Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res 29:317-28
Jennis, Matthew; Kung, Che-Pei; Basu, Subhasree et al. (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 30:918-30
Chatwichien, Jaruwan; Basu, Subhasree; Budina-Kolomets, Anna et al. (2016) PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline. Bioorg Med Chem Lett 26:4884-4887
Krepler, Clemens; Xiao, Min; Sproesser, Katrin et al. (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592-602

Showing the most recent 10 out of 87 publications